Search research articles
Contact Us
Filters
Showing results (211-220 of 453) with videos related to
Page
of 46
Sort By:
Neuro-Oncology
|
March 29, 2018
Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686
Jerrold L Boxerman, Zheng Zhang, Yair Safriel, et al.
Neuro-Oncology
|
June 22, 2013
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study
Jerrold L Boxerman, Zheng Zhang, Yair Safriel, et al.
Journal of Neuro-Oncology
|
July 25, 2020
Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor Section
John Lynes, Alvina A Acquaye, Hannah Sur, et al.
Cancers
|
October 16, 2025
Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. <i>Cancers</i> 2020, <i>12</i>, 1935
Emeline Tabouret, Herui Wang, Niranjana Amin, et al.
Nature Communications
|
May 31, 2018
Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade
Winson S Ho, Herui Wang, Dominic Maggio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 23, 2014
Reply to M.C. Chamberlain
Mark R Gilbert, James Dignam, Stephanie Pugh, et al.
Journal of Neuro-Oncology
|
May 17, 2018
Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM
Lindsay S Rowe, John A Butman, Megan Mackey, et al.
Journal of Neuro-Oncology
|
April 30, 2014
Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing
Betty Y S Kim, Wen Jiang, Jason Beiko, et al.
Journal of Neuro-Oncology
|
April 29, 2020
Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma
Dominic Maggio, Winson S Ho, Rebecca Breese, et al.
Journal of Neuro-Oncology
|
July 9, 2011
Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery
Mark R Gilbert, John Kuhn, Kathleen R Lamborn, et al.
Page
of 46
Search research articles
Search
Showing results (211-220 of 453) with videos related to
Sort By:
Page
of 46
Neuro-Oncology
|
March 29, 2018
Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686
Jerrold L Boxerman, Zheng Zhang, Yair Safriel, et al.
Neuro-Oncology
|
June 22, 2013
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study
Jerrold L Boxerman, Zheng Zhang, Yair Safriel, et al.
Journal of Neuro-Oncology
|
July 25, 2020
Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor Section
John Lynes, Alvina A Acquaye, Hannah Sur, et al.
Cancers
|
October 16, 2025
Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. <i>Cancers</i> 2020, <i>12</i>, 1935
Emeline Tabouret, Herui Wang, Niranjana Amin, et al.
Nature Communications
|
May 31, 2018
Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade
Winson S Ho, Herui Wang, Dominic Maggio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 23, 2014
Reply to M.C. Chamberlain
Mark R Gilbert, James Dignam, Stephanie Pugh, et al.
Journal of Neuro-Oncology
|
May 17, 2018
Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM
Lindsay S Rowe, John A Butman, Megan Mackey, et al.
Journal of Neuro-Oncology
|
April 30, 2014
Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing
Betty Y S Kim, Wen Jiang, Jason Beiko, et al.
Journal of Neuro-Oncology
|
April 29, 2020
Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma
Dominic Maggio, Winson S Ho, Rebecca Breese, et al.
Journal of Neuro-Oncology
|
July 9, 2011
Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery
Mark R Gilbert, John Kuhn, Kathleen R Lamborn, et al.
Page
of 46